Bone health · Long-term oral corticosteroids
Long-Term Oral Steroids and Bone Health: What to Ask About Risk Assessment
Oral glucocorticoids can raise fracture risk, sometimes early in treatment. Learn what current guidance says clinicians may assess, what a DXA scan can and cannot tell you, and why prescribed steroids should never be stopped or tapered without medical advice.
A useful medication can carry a bone-health question
A glucocorticoid medicine such as prednisone can be an important treatment for asthma, inflammatory disease, severe allergic reactions, and other conditions. When these medicines are taken by mouth for a prolonged period, bone health deserves a conversation too. That does not mean a fracture is inevitable, that every person needs the same test, or that a prescription should be stopped. Risk depends on the dose, duration, underlying illness, age, prior fractures, and other factors. This guide explains the questions that may help a patient and prescriber discuss bone risk while keeping control of treatment decisions with the qualified care team.
Which medicines are meant by ‘steroids’ here?
In this article, “steroids” means glucocorticoids—medicines related to cortisol, such as prednisone or prednisolone, dexamethasone, and methylprednisolone. It does not mean anabolic steroids used to build muscle. Glucocorticoids may be given as tablets, liquid, or an injection that has effects throughout the body; inhaled, nasal, and skin preparations are different forms with different patterns of exposure. A medication label and a clinician or pharmacist can clarify what a person is taking. Do not use a general article to infer that one route or dose is risk-free, or to compare your treatment with someone else’s.
Why ongoing glucocorticoids can affect bones
Bone is living tissue that is continually renewed. Glucocorticoids can disrupt that balance, reducing bone formation and increasing bone loss. The National Osteoporosis Guideline Group (NOGG) notes that bone loss and fracture risk can rise early after oral glucocorticoids begin. The American College of Rheumatology (ACR) guideline also describes dose- and duration-related fracture concerns. These are group-level findings, not a forecast for an individual. They explain why clinicians may ask about bone health before or soon after longer-term treatment starts rather than waiting for a fracture or for a person to feel a change in bone strength.
Risk depends on the full picture, not one number
There is no single dose threshold that can determine one person’s outcome. The ACR guideline addresses adults beginning or continuing glucocorticoids equivalent to at least 2.5 milligrams of prednisone per day for more than three months. It recommends an initial fracture-risk assessment for this group. Other guidance uses different thresholds for particular treatment decisions and populations. A previous fragility fracture, older age, menopause, low body weight, falls, smoking, alcohol use, family history, and other health conditions can also matter. A threshold in a guideline helps organize care; it is not permission to self-diagnose or a reason to change a prescribed dose.
A short course is not the same as ongoing treatment
Evidence and recommendations differ for brief bursts, repeated courses, injections, inhalers, and long-term oral treatment. A one-time short course should not automatically be treated as equivalent to months of daily tablets, while several courses or a high-dose treatment plan may still deserve a conversation. The Royal Osteoporosis Society explains that duration, dose, and route influence risk and that the exact risk from a short course is not the same for everyone. If you have received repeated courses or expect a longer course, tell the prescriber about previous steroid use and fractures. They can interpret the pattern in the context of the condition being treated.
Why a medication conversation matters more than stopping
Concern about bone effects should lead to a medication review—not an unsupervised stop. After longer-term steroid use, suddenly stopping can be dangerous because the body may need time to resume its own hormone production. The NHS advises following a prescriber’s plan, which may include a gradual taper; the right schedule depends on the medicine and the person. Do not skip, reduce, double, or share doses, and do not add an osteoporosis medicine or supplement based only on this article. If you are worried about a side effect, contact the clinician who prescribed the medicine or a pharmacist promptly and ask what to do while you wait.
What a fracture-risk assessment may include
For adults taking prolonged glucocorticoids, ACR guidance describes a clinical fracture-risk assessment as well as bone-density testing, often with a vertebral fracture assessment or spine X-rays. For adults aged 40 and older, clinicians may also use FRAX, a tool that estimates fracture probability from several risk factors and can account for glucocorticoid exposure. These tools inform a conversation; they do not diagnose why a person has pain or make treatment choices on their own. A clinician may use a different approach for younger adults, children, people who may become pregnant, or those with a prior fracture or very high-dose exposure.
Where DXA and spine imaging fit
A DXA scan estimates bone mineral density at specific sites, commonly the hip and spine. It is one piece of information, not a complete measure of bone strength or an automatic answer about treatment. A vertebral fracture assessment or spine image may be considered because some spine fractures cause few obvious symptoms. NOGG identifies factors such as long-term oral glucocorticoid use, height loss, a curved upper back, and new back pain as reasons clinicians may consider imaging in some adults. A prior DXA result can be useful, but the date, body site, machine, and clinical context matter when comparing results.
Timing can matter, especially early in treatment
Timing is worth asking about. ACR guidance recommends assessment as soon as possible after starting or continuing a qualifying prolonged regimen; the guideline describes completing the initial assessment within six months of starting. The NOGG guideline also emphasizes that fracture risk can rise early after oral treatment begins. This does not mean everyone should wait six months or that an online article can set an appointment deadline. If a prolonged course is planned, ask the prescriber whether bone risk should be reviewed now, when any test might be useful, and who will coordinate it. If treatment has already been underway for months, a conversation can still clarify next steps.
Bring the rest of the health history into view
A useful review considers more than medication. Share a history of fractures after a minor fall, height loss, family history of hip fracture, falls or balance problems, menstrual or hormone changes, smoking, alcohol, kidney or digestive conditions, and medicines that may affect bone. Bring a current medication and supplement list, including the glucocorticoid dose and start date if known. Ask whether a test for another cause of bone loss is appropriate. Do not order broad lab panels or start high-dose calcium or vitamin D on your own: supplements can have risks, interact with medicines, or be unsuitable for some kidney conditions.
Everyday habits can support—but not replace—assessment
Regular movement, strength and balance activity, avoiding tobacco, limiting alcohol, and getting adequate nutrients are often part of a broader bone-health plan. The safest activity depends on pain, fracture history, mobility, and other conditions. A clinician or physical therapist can help someone choose an appropriate starting point, especially if there has been a spine or hip fracture. Food and supplements should be considered in light of the person’s diet and medical history. These habits can support general health, but they cannot cancel the effects of a medication or replace a fracture-risk assessment when one is appropriate.
Bone-protective treatment is an individualized decision
If assessment shows elevated fracture risk, a clinician may discuss medicine to protect bone. ACR recommendations include prescription options for people at moderate, high, or very high risk, while NOGG’s pathway uses its own population-specific risk thresholds. Choice depends on age, pregnancy potential, kidney function, fracture history, other medicines, expected steroid duration, and patient preference. Benefits, side effects, monitoring, and what happens when either medicine is stopped all deserve explanation. This article cannot identify the correct treatment. A low DXA score is not the only factor, and a normal or near-normal result does not automatically remove all risk.
A practical checklist for the next appointment
Before an appointment, write down: the name and dose of each glucocorticoid; how often you have used it; the reason for treatment; previous fractures or height loss; falls; and any older DXA or spine-imaging results. Then consider asking: ‘How long do you expect this course to continue?’ ‘Does my treatment history warrant a fracture-risk review?’ ‘Would DXA, vertebral imaging, or another assessment help in my situation?’ ‘If a test is normal, should anything be rechecked later?’ ‘Who should I contact if the steroid dose changes?’ These questions invite shared decision-making without assuming a diagnosis or a particular treatment.
When new back or hip pain needs prompt attention
New severe back pain after a minor movement, a fall with hip or groin pain, a sudden loss of height, or inability to stand or bear weight merits timely professional assessment. Severe pain after a significant injury, new weakness or numbness, loss of bladder or bowel control, or another rapidly worsening symptom may require urgent or emergency care. These symptoms do not prove a fracture, and the list is not exhaustive. If you are unsure how urgent a change is, use local medical advice or emergency services rather than waiting for an online article or trying to adjust medication yourself.
Keep commercial program pages separate from medical guidance
The site’s existing Bone Density Solution, Arthritis Strategy, and Banishing Bronchitis pages are optional commercial reading, not clinical references or recommendations. Their presence does not mean a program can assess fracture risk, interpret a DXA result, prevent steroid-related bone loss, or replace care for the condition a steroid treats. Marketing material is separate from the public guidelines listed below. No purchase is needed to use the information in this article, and no commercial program should be used to delay evaluation or change a prescribed medicine.
The takeaway: ask early, and do not change a prescription alone
The practical takeaway is to raise bone health early if you expect to take oral glucocorticoids for months, have repeated courses, or have other fracture risk factors. A clinician can interpret dose and duration, review your history, and decide whether assessment or prevention is appropriate under current local guidance. Do not stop or taper a prescribed steroid on your own, and do not self-prescribe supplements or bone medicines. This is general health education, not diagnosis, personal medical advice, or a treatment plan. Mr.Hotsia’s editorial review is limited to source checking and clarity; it is not clinical review, and no medical credentials are implied.
Sources and further reading
Medical information was checked against these public health sources on November 9, 2026.
- American College of Rheumatology — 2022 Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (published 2023) ↗
- NOGG 2024 — Section 7: Strategies for Management of Osteoporosis and Fracture Risk ↗
- NOGG 2024 — Section 3: Fracture Risk Assessment and Case Finding ↗
- NHS — Steroids: side effects and stopping safely ↗
- Royal Osteoporosis Society — Steroids (glucocorticoids) and bone health ↗
- Bone Health & Osteoporosis Foundation — What Is Osteoporosis and What Causes It? ↗
- Endocrine Society — Glucocorticoid-Induced Osteoporosis ↗
This article is general health education, not a diagnosis or personal medical advice. Do not change treatment or supplements based on this article. Discuss individual results with a qualified healthcare professional.